百花医药
(600721)
| 流通市值：33.80亿 | | | 总市值：33.80亿 |
| 流通股本：3.85亿 | | | 总股本：3.85亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 88,254,265.22 | 126,140,297.03 | 67,613,090.24 | 272,048,128.25 |
| 交易性金融资产 | 180,450,000 | 127,700,000 | 177,850,000 | - |
| 应收票据及应收账款 | 118,019,060.9 | 114,255,124.46 | 112,049,691.64 | 84,796,881.78 |
| 其中：应收票据 | 9,036,287.06 | 7,426,587.94 | 6,330,152.91 | 3,832,188.91 |
| 应收账款 | 108,982,773.84 | 106,828,536.52 | 105,719,538.73 | 80,964,692.87 |
| 应收款项融资 | 10,272,546.74 | 10,747,352.78 | 5,834,378.32 | 5,934,432.39 |
| 预付款项 | 4,053,504 | 4,285,382.01 | 7,391,206.93 | 3,017,390.57 |
| 其他应收款合计 | 4,312,133.59 | 4,317,006.61 | 4,686,947.89 | 3,700,344.67 |
| 存货 | 74,523,136.14 | 86,222,104.89 | 104,429,899.38 | 99,723,149.71 |
| 合同资产 | 95,999,205.22 | 97,366,239.11 | 99,429,233.77 | 111,303,976.88 |
| 其他流动资产 | 2,701,005.6 | 3,093,372.83 | 2,732,747.91 | 2,747,572.44 |
| 流动资产合计 | 578,584,857.41 | 574,126,879.72 | 582,017,196.08 | 583,271,876.69 |
| 非流动资产: | | | | |
| 长期股权投资 | 59,250,475.47 | 59,883,701.87 | 59,904,214.67 | 59,910,943.3 |
| 其他权益工具投资 | 7,661,309.55 | 5,761,309.55 | 3,861,309.55 | 3,861,309.55 |
| 投资性房地产 | 245,250,300 | 245,250,300 | 245,250,300 | 245,250,300 |
| 固定资产 | 140,697,878.9 | 143,713,396.25 | 141,218,081.72 | 140,026,004.25 |
| 使用权资产 | - | - | 31,638.45 | 79,096.11 |
| 无形资产 | 7,075,105.55 | 7,565,875.85 | 7,957,887.26 | 8,413,998.95 |
| 开发支出 | 36,681,402.28 | 34,974,516.7 | 31,481,083.12 | 27,482,385.83 |
| 商誉 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 | 11,485,077.64 |
| 长期待摊费用 | 2,251,442.42 | 2,162,300.02 | 2,418,079.6 | 2,705,109.19 |
| 递延所得税资产 | 31,107,654.94 | 31,052,273.48 | 31,785,866.31 | 31,776,278.38 |
| 其他非流动资产 | 599,897.16 | 576,587.09 | 3,863,755.23 | 281,716.26 |
| 非流动资产合计 | 542,060,543.91 | 542,425,338.45 | 539,257,293.55 | 531,272,219.46 |
| 资产总计 | 1,120,645,401.32 | 1,116,552,218.17 | 1,121,274,489.63 | 1,114,544,096.15 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 84,195,719.52 | 86,565,734.35 | 91,208,448.98 | 86,651,748.4 |
| 应付账款 | 84,195,719.52 | 86,565,734.35 | 91,208,448.98 | 86,651,748.4 |
| 合同负债 | 124,348,586.08 | 126,450,170.69 | 134,795,954.56 | 140,505,029.12 |
| 应付职工薪酬 | 21,630,980.91 | 19,477,121.6 | 15,594,033.62 | 27,347,408.03 |
| 应交税费 | 4,101,147.41 | 5,106,507.53 | 3,383,838.75 | 4,070,131.29 |
| 其他应付款合计 | 34,499,641.68 | 35,279,590.74 | 39,715,803.81 | 40,783,796.36 |
| 应付股利 | 121,146.5 | 121,146.5 | 121,146.5 | 121,146.5 |
| 一年内到期的非流动负债 | - | - | 38,770.93 | 96,927.31 |
| 其他流动负债 | 9,133,034.01 | 10,511,847.62 | 9,369,419.94 | 9,666,042.49 |
| 流动负债合计 | 277,909,109.61 | 283,390,972.53 | 294,106,270.59 | 309,121,083 |
| 非流动负债: | | | | |
| 长期应付职工薪酬 | 1,132,375.37 | 1,148,876.99 | 1,160,336.76 | 1,163,724.45 |
| 预计负债 | 1,097,589.71 | 1,097,589.71 | 1,097,589.71 | 1,097,589.71 |
| 递延收益 | 1,569,400.03 | 968,465.25 | 1,014,215.25 | 1,059,965.25 |
| 递延所得税负债 | 45,116,277.24 | 44,580,214.35 | 44,037,233.09 | 43,520,015.45 |
| 非流动负债合计 | 48,915,642.35 | 47,795,146.3 | 47,309,374.81 | 46,841,294.86 |
| 负债合计 | 326,824,751.96 | 331,186,118.83 | 341,415,645.4 | 355,962,377.86 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 384,547,635 | 384,293,875 | 384,144,335 | 384,032,635 |
| 资本公积 | 2,267,881,103.37 | 2,266,871,138.57 | 2,266,275,969.37 | 2,265,831,403.37 |
| 其他综合收益 | 7,195,146.14 | 7,195,146.14 | 7,195,146.14 | 7,195,146.14 |
| 盈余公积 | 5,030,274.41 | 5,030,274.41 | 5,030,274.41 | 5,030,274.41 |
| 未分配利润 | -1,870,833,509.56 | -1,878,024,334.78 | -1,882,786,880.69 | -1,903,507,740.63 |
| 归属于母公司股东权益合计 | 793,820,649.36 | 785,366,099.34 | 779,858,844.23 | 758,581,718.29 |
| 股东权益合计 | 793,820,649.36 | 785,366,099.34 | 779,858,844.23 | 758,581,718.29 |
| 负债和股东权益合计 | 1,120,645,401.32 | 1,116,552,218.17 | 1,121,274,489.63 | 1,114,544,096.15 |
| 公告日期 | 2025-10-28 | 2025-08-22 | 2025-04-26 | 2025-03-12 |
| 审计意见(境内) | | | | 标准无保留意见 |